linjc16/ctgov huggingface dataset:
Association of Genetic Polymorphism and Acute Kidney Injury After Liver Transplantation

Study Overview
=================
Brief Summary
-----------------
Some of the liver transplantation recipients experience postoperative acute kidney injury due to various causes including genetic factors. Prevention of postoperative acute kidney injury is essential for postoperative care in liver transplantation recipients. The aim of this study is to investigate the relationship between gene polymorphisms which have been known to be associated with postoperative acute kidney injury, and the occurrence of acute kidney injury after liver transplantation.

Conditions
-----------------
Liver Transplantation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1) adult patients scheduled for liver transplantation Exclusion Criteria: Patients on dialysis patients not able to read, or understand the consent form ethnicity, other than asian patients refusal

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Recipients undergoing liver transplantation<br>Patients undergoing liver transplantation will be included and followed up during the first 72 hours post-liver transplantation in order to confirm the development of acute kidney injury. The patients will be divided into two groups (AKI group vs. non-AKI group) according to the development of acute kidney injury. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Acute kidney injury after liver transplantation | The development of acute kidney injury is defined by the following definition: 50% increase in SCr from the baseline (preoperative value) or a 0.3 mg/dl increase from baseline within 48 h without urine output. The development of acute kidney injury after liver transplantation could correlate with gene polymorphisms, which have been known to be associated with postoperative acute kidney injury. | 72 hours |
Thyroid Dysfunction and Obstetric Complications

Study Overview
=================
Brief Summary
-----------------
Obstetric complications are common and can be responsible for maternal and foetal morbidity and mortality. Thyroid dysfunction has been identified as a possible cause of obstetric complications. Many studies have been conducted to estimate the prevalence and define the nature of obstetric complications observed in patients with thyroid dysfunction. However, women with obstetric complications are not systematically screened for thyroid dysfunction and no published study has evaluated the prevalence of thyroid dysfunction in women with an obstetric complication. As no consensus has been reached concerning systematic screening for thyroid dysfunction in pregnant women, the identification of new high-risk populations could possibly result in a change of clinical practice.

Official Title
-----------------
Thyroid Dysfunction and Obstetric Complications

Conditions
-----------------
Pregnancy

Intervention / Treatment
-----------------
* Biological: blood samples


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: women attending the emergency room and/or hospitalised or followed for: Spontaneous and/or repeated miscarriage Foetal death Pre-eclampsia Retroplacental haematoma Post-partum haemorrhage Premature delivery who consent to participate in the study. Assessment of these women will include blood samples for a laboratory work-up and anti-thyroid antibodies. Exclusion Criteria: normal pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| women<br>attending the emergency room and/or hospitalised or followed for: Spontaneous and/or repeated miscarriage Foetal death Pre-eclampsia Retroplacental haematoma Post-partum haemorrhage Premature delivery Blood samples | Biological: blood samples<br>* for the determination of thyroid hormones (TSH, FT3, FT4 ) and antibodies against the thyroid (anti TPO antibodies and anti thyroglobulin)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of thyroid dysfunction | Estimate the overall and individual prevalence of thyroid dysfunction (hypothyroidism, hyperthyroidism and thyroid autoimmunity) in patients with obstetrical accident | Day 0 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Thyroid dysfunction, obstetric complications
An Efficacy Study of BCS Clearing the Oral Colonized Bacterium in Hospitalized Patients With COPD

Study Overview
=================
Brief Summary
-----------------
The purpose of study is to evaluate the efficacy and safety of Benzalkonium Chloride Solution clearing the oral colonized bacterium in hospitalized patients with COPD.

Detailed Description
-----------------
This a randomized, double-blind, parallel, single-center, exploratory trial. 60 patients will be randomized to two treatments: benzalkonium chloride solution treatment or normal saline treatment.The purpose of study is to evaluate the efficacy and safety of benzalkonium chloride solution clearing the oral colonized bacterium in hospitalized patients with COPD.

Official Title
-----------------
An Efficacy Study of Benzalkonium Chloride Solution Clearing the Oral Colonized Bacterium in Hospitalized Patients With COPD

Conditions
-----------------
Chronic Obstructive Pulmonary Disease

Intervention / Treatment
-----------------
* Drug: Benzalkonium chloride solution
* Drug: Normal saline


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: COPD patients in hospitalized. Aged from18 to 70 years (including 18 and 70). Patients participating in this trial should sign ICFs. Patients with good understanding, could conduct this study with investigators. Exclusion Criteria: History of mouthwash allergies, allergic rhinitis or dermatitis. Patients with oral ulcers, severe periodontal disease, oral mucosal lesions or oral cancer, patients received special oral clean. Patients with removable denture. Patients with malignant blood diseases. History of using cytotoxic drugs or biological immunosuppressants ( such as TNF-α inhibitors ). Had used clinical study drugs before 28 days enrollment. Had used clinical study drugs before 28 days enrollment.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Benzalkonium chloride solution<br>Tid, for 7 days. | Drug: Benzalkonium chloride solution<br>* Tid, 7 days<br>* Other names: You Ke Shi;|
| Active Comparator: Normal saline<br>Tid, for 7 days. | Drug: Normal saline<br>* Tid, 7 days<br>* Other names: NS;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Aerobic pathogenic bacterial colonization rate in oral airway |  | Day 7 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The improvement of oral status |  | Day 7 | 
| The subjective feeling |  | Day 7 | 
| The incidence of hospital acquired respiratory infections |  | Day 7 |
Comparison of Beck Depression Score in Multipar and Nulliparous Women Who Have Gone Under Dilatation and Curettage

Study Overview
=================
Brief Summary
-----------------
It is aimed to compare the beck depression and anxiety values of the nulliparous and multipar pregnant women who undergo optional abortion below 12 weeks and to evaluate the effect of the parity on depression and anxiety.

Detailed Description
-----------------
The beck depression and anxiety scale consists of questionnaire questions asked to the patient, and the value on 17 indicates advanced depression. The BDI inventory has maximum of 63 and minimum of 0 scores: (0-10): Are considered normal ups and downs (11-16): Mild mood disturbance (17-20): Borderline clinical depression (21-30): Moderate depression, (31-40): Severe depression, Over 40: Extreme depression. A persistent score of !17, requires psychiatric treatment

Official Title
-----------------
Comparison of Beck Depression Score in Multipar and Nulliparous Women Who Have Gone Under Dilatation and Curettage

Conditions
-----------------
Depression, Anxiety Depression, Pregnancy Early

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy Women with a pregnancy less than 12 weeks no psychiatric disease or drug use Exclusion Criteria: Those who have had a psychiatric diagnosis before, Women under the age of 18, Psychiatric drug users, Those who have experienced a major trauma or disease During the 3-month follow-up period, who developed complications during the procedure pregnant again Women with a pregnancy greater than 12 weeks

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Nullipar pregnant women<br> | |
| multipar pregnant women<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparison of Beck Depression and Anxiety Scores in Multipar and Nulliparous Women who have gone under Dilatation and Curettage | to evaluate the effect of the parity on depression and anxiety. The BDI inventory has maximum of 63 and minimum of 0 scores: (0-10): Are considered normal ups and downs (11-16): Mild mood disturbance (17-20): Borderline clinical depression (21-30): Moderate depression, (31-40): Severe depression, Over 40: Extreme depression. A persistent score of !17, requires psychiatric treatment | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Beck Depression, Beck Anxiety, parite, curettage
Genetic Factors Affecting the Severity of Beta Thalassemia

Study Overview
=================
Brief Summary
-----------------
Patients with genetic diseases can have widely differing severities. We are looking for genetic factors which influence the severity of beta thalassemia.

Detailed Description
-----------------
The understanding of the phenotypic variability of genetically homogeneous disorders represents a major challenge. In beta thalassemia, the beta globin gene is affected by a variety of mutations. The group of patients to be analyzed here is homozygous for a splice site mutation that is common in the Middle East. In contrast to this genetic homogeneity, the spectrum of the clinical phenotype ranges from mild anemia to most severe, transfusion dependent anemia. We will use a genetic linkage approach to identify modifying factors and by analyzing the efficiency of an mRNA surveillance mechanism that is referred to as nonsense-mediated decay and represents a candidate genetic modifier of beta thalassemia and other genetic disorders.

Official Title
-----------------
Identification of Novel Genetic Modifiers in Beta-thalassemia

Conditions
-----------------
Beta Thalassemia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Identification of homozygous IVS1 nt 6 beta thalassemia mutation
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Aspirin in the Prevention of Cardiovascular Events in Hemodialysis Patients

Study Overview
=================
Brief Summary
-----------------
The study is prospectively initiated to: (1) evaluate the alterations in platelet function to aspirin therapy and the prevalence of aspirin resistance in patients with chronic kidney disease undergoing hemodialysis, and (2) compare the incidence of vascular events (myocardial infarction, cardiac death, stroke, vascular access thrombosis, or revascularization procedure) and the safety profile among placebo-treated, aspirin-resistant and aspirin-sensitive patients.

Official Title
-----------------
Efficacy of Monitoring of Aspirin Responsiveness in the Prevention of Cardiovascular Events and Decrease in Bleeding Complications in Patients With End-Stage Kidney Disease Undergoing Hemodialysis

Conditions
-----------------
End-Stage Renal Disease

Intervention / Treatment
-----------------
* Drug: aspirin
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with end-stage renal disease who are undergoing long-term hemodialysis. Exclusion Criteria: Patients will be excluded if there is evidence of a recent history of acute uremia, previous adverse reaction to a aspirin or history of aspirin hypersensitivity (eg, aspirin-induced asthma or angioedema), concurrent treatment with other antiplatelet agent (clopidogrel or ticlopidine), steroidal drugs, or nonsteroidal anti-inflammatory drugs, high immediate risk for bleeding (eg, active peptic ulceration, recent injury, or hemophilia), or life-threatening condition other than end-stage renal disease or vascular disease (eg, non-skin cancer).

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Aspirin<br> | Drug: aspirin<br>* aspirin 100 mg qd for 3 years<br>|
| Placebo Comparator: Sugar pills<br>Hemodialysis (HD) patients receive placebo not containing aspirin in this study. | Drug: Placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the prevalence of aspirin resistance |  | 3 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the incidence of vascular events (myocardial infarction, cardiac death, stroke, vascular access thrombosis, or revascularization procedure) |  | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
aspirin, aspirin resistance, hemodialysis, cardiovascular, Prevalence of aspirin resistance, cardiovascular events, and safety profile
Compassionate Use of Sodium Stibogluconate (Pentostam) for Cutaneous and Mucocutaneous New World Leishmaniasis

Study Overview
=================
Brief Summary
-----------------
Patients with biopsy proven new world cutaneous or mucocutaneous leishmaniasis will be treated with sodium stibogluconate (Pentostam).

Official Title
-----------------
Compassionate Use of Sodium Stibogluconate (Pentostam) for Cutaneous and Mucocutaneous New World Leishmaniasis

Conditions
-----------------
Leishmaniasis, Cutaneous, Leishmaniasis, Mucocutaneous

Intervention / Treatment
-----------------
* Drug: sodium stibogluconate (Pentostam)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Biopsy proven new world cutaneous or mucocutaneous leishmania Exclusion Criteria: Prolonged QT Liver disease Pancreatitis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: sodium stibogluconate (Pentostam)|20 mg/kg IV every day for 20 or 28 days|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
New World Cutaneous or Mucocutaneous Leishmaniasis
Medical Education in a Private Hospital

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess patient and companion acceptability of medical education in a non-teaching private hospital

Official Title
-----------------
Patient and Companion Perspectives on Medical Education in a Non-Teaching Private Hospital

Conditions
-----------------
Health Care Quality, Access, and Evaluation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients in the hospital ward and in the emergency waiting room Family members of patients admitted to the intensive care unit
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Ward<br>Patients in the hospital ward | |
| Emergency room<br>Patients in the emergency waiting room | |
| Intensive care unit<br>Family members of patients admitted to the intensive care unit | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient and companion acceptability of medical education |  | immediate | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Medical students, Medical education, Private hospital, Patient satisfaction, Questionnaires
The Effect of Transaortic Valve Replacement on the Endothelial Integrity and Function

Study Overview
=================
Brief Summary
-----------------
Degenerative aortic valve stenosis (AVS) is the leading cause of aortic valve morbidity with a prevalence of 2-7% at ages above 65 years, with ever-increasing incidence especially in the 8th decades. AVS is independently associated with atheroclerosis risk factors and clinically apparent CV disease indicating that the degeneration of the aortic valve may represent an atheroclerosis-like process involving both, the aortic valve as well as the vascular system, respectivel. It is still unknown whether the endothelial function is affected as an manifestation of the atherosclerotic process, changes in the driving mechanical forces as WSS downstream of the valve, or other factors beyond physical pressure effects. The investigators hypothesized that altered haemodynamics may at least partly be responsible for observed endothelial dysfunction in patients with AVS. Therefore, the aim of this study is to investigate whether the resolution of AVS by transaortic valve implacement (TAVI) affects WSS, improves endothelial dysfunction and decreases levels of circulating EMPs as markers of endothelial integrity.

Official Title
-----------------
The Effect of Transaortic Valve Replacement on the Endothelial Integrity and Function

Conditions
-----------------
Degenerative Aortic Valve Stenosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: aortic valve stenosis screened for TAVI written informed consent Exclusion Criteria: no written informed consent Patients with acute infections (CRP> 0.5 mg / dL) Patients with Atrial Fibrillation Patients with inflammatory and malignant diseases

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| endothelial function | endothelial function will be measured by flow mediated dilation (FMD) | Changes from Baseline in endothelial function at 3 months | 
| plasma levels of circulating microparticles (MPs) |  | Changes from Baseline in Plasma Levels of MPs at 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| arterial stiffness | arterial stiffness will be measured by pulse wave analysis | Changes from Baseline in arterial stiffness at 3 months | 
| blood pressure |  | Changes from Baseline in Hemodynamics at 3 months | 
| heart rate |  | Changes from Baseline in Hemodynamics at 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
transaortic valve replacement (TAVI), endothelial function, circulating microparticles